Non-alcoholic fatty liver disease (NAFLD) is a frequent accompaniment of obesity and
insulin resistance. With the prevalence approaching 85% in obese populations, new
therapeutic approaches to manage NAFLD are warranted. A systematic search of the
literature was conducted for studies pertaining to the effect of omega-3 polyunsaturated fatty
acid (PUFA) supplementation on NAFLD in humans. Primary outcome measures were liver
fat and liver function tests: alanine aminotransferase (ALT) and aspartate aminotransferase …